---
figid: PMC6499508__nqy356fig6
figlink: /pmc/articles/PMC6499508/figure/fig6/
number: F6
caption: 'Graphical summary. Hypothetic physiologic changes that occur when replacing
  SFAs with PUFAs diet, as outlined in the Discussion. Annotations: bold grey, no
  difference; plain grey (nonbold), not measured; bold blue, increased/higher; bold
  red, reduced/lower; italics: gene names. Possible sequence of events: replacing
  SFAs with PUFAs changes the expression of LDLR, possibly via SREBP2 or other regulatory
  mechanisms. Higher expression of LDLR causes a higher hepatic uptake of apoB-containing
  lipoproteins, which reduces plasma lipoprotein subclasses, both apoB- and apoAI-containing
  types. This effect may be partially offset by higher expression of PCSK9. In PBMCs,
  controlled LXR activation may drive an increase in reverse cholesterol transport,
  which includes synthesis of fatty acids for efflux or to esterify free cholesterol
  to cholesteryl esters; normally, this would also correspond to an inhibition of
  β oxidation and modulation of inflammation-related gene expression. Higher hepatic
  cholesterol uptake both inhibits cholesterol synthesis, and activates cholesterol
  efflux to the gut. Cholesterol-derived oxysterols activate LXR, which activates
  the bile salt production. Other bile constituents are also produced, particularly
  from cysteine and other amino acids. Hepatic acetyl-CoA likely adjusts to a lower
  need for cholesterol synthesis, and directs energy surplus to production of primary
  ketone bodies. In addition, lower SFA influx requires less immediate neutralization
  via the β oxidation pathway, which could be reflected in lower hepatic oxidative
  stress. Abbreviations as in –.'
pmcid: PMC6499508
papertitle: Using metabolic profiling and gene expression analyses to explore molecular
  effects of replacing saturated fat with polyunsaturated fat—a randomized controlled
  dietary intervention study.
reftext: Stine M Ulven, et al. Am J Clin Nutr. 2019 May;109(5):1239-1250.
pmc_ranked_result_index: '50112'
pathway_score: 0.9659357
filename: nqy356fig6.jpg
figtitle: Graphical summary
year: '2019'
organisms:
- Mus musculus
- Cavia porcellus
- Luscinia megarhynchos
- Olea europaea
- Helianthus annuus
- Candida dubliniensis
- Homo sapiens
ndex: 1482d9de-dec3-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6499508__nqy356fig6.html
  '@type': Dataset
  description: 'Graphical summary. Hypothetic physiologic changes that occur when
    replacing SFAs with PUFAs diet, as outlined in the Discussion. Annotations: bold
    grey, no difference; plain grey (nonbold), not measured; bold blue, increased/higher;
    bold red, reduced/lower; italics: gene names. Possible sequence of events: replacing
    SFAs with PUFAs changes the expression of LDLR, possibly via SREBP2 or other regulatory
    mechanisms. Higher expression of LDLR causes a higher hepatic uptake of apoB-containing
    lipoproteins, which reduces plasma lipoprotein subclasses, both apoB- and apoAI-containing
    types. This effect may be partially offset by higher expression of PCSK9. In PBMCs,
    controlled LXR activation may drive an increase in reverse cholesterol transport,
    which includes synthesis of fatty acids for efflux or to esterify free cholesterol
    to cholesteryl esters; normally, this would also correspond to an inhibition of
    β oxidation and modulation of inflammation-related gene expression. Higher hepatic
    cholesterol uptake both inhibits cholesterol synthesis, and activates cholesterol
    efflux to the gut. Cholesterol-derived oxysterols activate LXR, which activates
    the bile salt production. Other bile constituents are also produced, particularly
    from cysteine and other amino acids. Hepatic acetyl-CoA likely adjusts to a lower
    need for cholesterol synthesis, and directs energy surplus to production of primary
    ketone bodies. In addition, lower SFA influx requires less immediate neutralization
    via the β oxidation pathway, which could be reflected in lower hepatic oxidative
    stress. Abbreviations as in –.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CCR2
  - CD36
  - BOK
  - ABCG1
  - APOA1
  - APOB
  - CBS
  - IDO1
  - MYLIP
  - IFNG
  - HMGCR
  - CETP
  - CHPT1
  - CPT2
  - IL18
  - ABCA1
  - APOA2
  - APOE
  - CLU
  - SREBF2
  - TDO2
  - TG
  - TLR4
  - TNF
  - LCAT
  - LDLR
  - PC
  - PCSK9
  - CXCR2
  - FASN
  - NR1H4
  - GATA3
  - ALB
  - UCP2
  - UPK2
  - PPARD
  - TNFSF14
  - SREBF1
  - SLC2A1
  - SCARB1
  - Tryptophan
  - Neopterin
  - Acetoacetate
  - Acetate
  - Kynurenine
  - Acetyl-CoA
  - Taurine
  - Glycine
  - ATP
  - GSH
  - Cysteine
  - Glutamate
  - Cystathionine
  - Serine A
  - Homocysteine
  - Malonyl-CoA
genes:
- word: CCR2
  symbol: CCR2
  source: hgnc_symbol
  hgnc_symbol: CCR2
  entrez: '729230'
- word: CD36
  symbol: CD36
  source: hgnc_symbol
  hgnc_symbol: CD36
  entrez: '948'
- word: B-ok.
  symbol: BOK
  source: hgnc_symbol
  hgnc_symbol: BOK
  entrez: '666'
- word: ABCG1
  symbol: ABCG1
  source: hgnc_symbol
  hgnc_symbol: ABCG1
  entrez: '9619'
- word: ApoA1
  symbol: APOA1
  source: hgnc_symbol
  hgnc_symbol: APOA1
  entrez: '335'
- word: ApoB
  symbol: APOB
  source: hgnc_symbol
  hgnc_symbol: APOB
  entrez: '338'
- word: CBS
  symbol: CBS
  source: hgnc_symbol
  hgnc_symbol: CBS
  entrez: '875'
- word: IDO
  symbol: IDO
  source: hgnc_prev_symbol
  hgnc_symbol: IDO1
  entrez: '3620'
- word: IDOL
  symbol: IDOL
  source: hgnc_alias_symbol
  hgnc_symbol: MYLIP
  entrez: '29116'
- word: IFNG
  symbol: IFNG
  source: hgnc_symbol
  hgnc_symbol: IFNG
  entrez: '3458'
- word: HMGCR
  symbol: HMGCR
  source: hgnc_symbol
  hgnc_symbol: HMGCR
  entrez: '3156'
- word: -CETP
  symbol: CETP
  source: hgnc_symbol
  hgnc_symbol: CETP
  entrez: '1071'
- word: CPT1
  symbol: CPT1
  source: hgnc_alias_symbol
  hgnc_symbol: CHPT1
  entrez: '56994'
- word: CPT2
  symbol: CPT2
  source: hgnc_symbol
  hgnc_symbol: CPT2
  entrez: '1376'
- word: IL18
  symbol: IL18
  source: hgnc_symbol
  hgnc_symbol: IL18
  entrez: '3606'
- word: ABCA1
  symbol: ABCA1
  source: hgnc_symbol
  hgnc_symbol: ABCA1
  entrez: '19'
- word: (HDL,)
  symbol: HDL
  source: bioentities_symbol
  hgnc_symbol: APOA2
  entrez: '336'
- word: (HDL,)
  symbol: HDL
  source: bioentities_symbol
  hgnc_symbol: APOE
  entrez: '348'
- word: (HDL,)
  symbol: HDL
  source: bioentities_symbol
  hgnc_symbol: CLU
  entrez: '1191'
- word: SREBF2
  symbol: SREBF2
  source: hgnc_symbol
  hgnc_symbol: SREBF2
  entrez: '6721'
- word: TDO
  symbol: TDO
  source: hgnc_alias_symbol
  hgnc_symbol: TDO2
  entrez: '6999'
- word: TG
  symbol: TG
  source: hgnc_symbol
  hgnc_symbol: TG
  entrez: '7038'
- word: TLR4
  symbol: TLR4
  source: hgnc_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: TNF
  symbol: TNF
  source: hgnc_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: LCAT
  symbol: LCAT
  source: hgnc_symbol
  hgnc_symbol: LCAT
  entrez: '3931'
- word: LDLR
  symbol: LDLR
  source: hgnc_symbol
  hgnc_symbol: LDLR
  entrez: '3949'
- word: PC
  symbol: PC
  source: hgnc_symbol
  hgnc_symbol: PC
  entrez: '5091'
- word: PCSK9
  symbol: PCSK9
  source: hgnc_symbol
  hgnc_symbol: PCSK9
  entrez: '255738'
- word: (HDL,)
  symbol: HDL
  source: bioentities_symbol
  hgnc_symbol: APOA1
  entrez: '335'
- word: CXCR2
  symbol: CXCR2
  source: hgnc_symbol
  hgnc_symbol: CXCR2
  entrez: '3579'
- word: FASN
  symbol: FASN
  source: hgnc_symbol
  hgnc_symbol: FASN
  entrez: '2194'
- word: FXR
  symbol: FXR
  source: hgnc_alias_symbol
  hgnc_symbol: NR1H4
  entrez: '9971'
- word: GATA3
  symbol: GATA3
  source: hgnc_symbol
  hgnc_symbol: GATA3
  entrez: '2625'
- word: (HDL,)
  symbol: HDL
  source: bioentities_symbol
  hgnc_symbol: ALB
  entrez: '213'
- word: ÚCP2
  symbol: UCP2
  source: hgnc_symbol
  hgnc_symbol: UCP2
  entrez: '7351'
- word: UP2
  symbol: UPII
  source: hgnc_alias_symbol
  hgnc_symbol: UPK2
  entrez: '7379'
- word: PPARD
  symbol: PPARD
  source: hgnc_symbol
  hgnc_symbol: PPARD
  entrez: '5467'
- word: TNFSF14
  symbol: TNFSF14
  source: hgnc_symbol
  hgnc_symbol: TNFSF14
  entrez: '8740'
- word: SREBF1-
  symbol: SREBF1
  source: hgnc_symbol
  hgnc_symbol: SREBF1
  entrez: '6720'
- word: CSE
  symbol: CSE
  source: hgnc_prev_symbol
  hgnc_symbol: SLC2A1
  entrez: '6513'
- word: SR-BI
  symbol: SR-BI
  source: hgnc_alias_symbol
  hgnc_symbol: SCARB1
  entrez: '949'
chemicals:
- word: Tryptophan
  source: ''
  identifier: ''
- word: Neopterin
  source: MESH
  identifier: D019798
- word: Acetoacetate
  source: MESH
  identifier: D000090
- word: Acetate
  source: MESH
  identifier: D000085
- word: Kynurenine
  source: MESH
  identifier: C029366
- word: Acetyl-CoA
  source: MESH
  identifier: D000105
- word: Taurine
  source: MESH
  identifier: D013654
- word: Glycine
  source: MESH
  identifier: D005998
- word: ATP
  source: MESH
  identifier: D000255
- word: GSH
  source: MESH
  identifier: D005978
- word: Cysteine
  source: MESH
  identifier: D003545
- word: Glutamate
  source: ''
  identifier: ''
- word: Cystathionine
  source: MESH
  identifier: D003540
- word: Serine A
  source: MESH
  identifier: C047902
- word: Homocysteine
  source: MESH
  identifier: D006710
- word: Malonyl-CoA
  source: MESH
  identifier: D008316
diseases: []
figid_alias: PMC6499508__F6
redirect_from: /figures/PMC6499508__F6
figtype: Figure
---
